Residue depletion profile and withdrawal interval estimation of ivermectin in eggs following topical administration of injectable ivermectin to domestic chickens (Gallus domesticus): a pilot study

注射用伊维菌素局部应用于家鸡(Gallus domesticus)后,鸡蛋中伊维菌素残留消耗情况及停药期估算:一项初步研究

阅读:3

Abstract

INTRODUCTION: Topical ivermectin is commonly prescribed extra-label for the control of mite infestations in backyard chicken flocks in the US. METHODS: Domestic laying hens (n = 8; 78 weeks of age, weight 1.7-2.2 kg) were administered injectable ivermectin solution topically over the jugular vein (0.4 mg/kg every 7 days for 2 doses). Ivermectin concentrations in egg white and egg yolk were determined using UPLC with fluorescence detection. RESULTS: The average period between eggs laid was 1.52 days. Ivermectin preferentially distributed to the egg yolk with an observed C (max) of 3.54 ng/g occurring at observed T (max) of 6.6 days and a T (1/2) of 9.5 days. Residues persisted at low concentrations in egg yolk for up to 71 days after the final dose. WDIs for the egg yolk matrix were estimated using the FDA, EMA, and terminal-elimination half-life multiplier methods (HLM). The longest estimated WDI was 102 days for the EMA 95/95 method (95% confidence interval for 95th population percentile) with the limit of detection (LOD; 0.03 ng/g) set as the maximum residue limit. The FDA 95/99 method using the LOD as the tolerance estimated an 81 day WDI, the HLM method estimated a 96 day WDI. DISCUSSION: This study improves the understanding of the residue depletion kinetics of ivermectin in eggs after topical administration to older hens with inconsistent egg production. Ivermectin is systemically absorbed following topical administration of the injectable formulation in domestic egg laying chickens, resulting in prolonged egg residues. Ivermectin is preferentially distributed to the egg yolk over the egg white following topical administration of the injectable formulation in egg laying chickens. Since plasma kinetics were not evaluated, the impact of systemic exposure on egg residue kinetics following topical administration remains unknown. The results provide insight into how the estimated ivermectin egg WDIs using regulatory methods differ based on the maximum residue limit/tolerance applied and portion of the terminal elimination phase sampled.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。